ABVC (ABVC BioPharma) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is ABVC BioPharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ABVC BioPharma's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.01.

ABVC BioPharma's long-term debt to total assets ratio declined from Sep. 2023 (0.13) to Sep. 2024 (0.01). It may suggest that ABVC BioPharma is progressively becoming less dependent on debt to grow their business.

ABVC BioPharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for ABVC BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABVC BioPharma LT-Debt-to-Total-Asset Chart

ABVC BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.35

0.08

0.03

ABVC BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.13	0.03	0.02	0.02	0.01

ABVC BioPharma LT-Debt-to-Total-Asset Calculation

ABVC BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.407	/	14.493
	=	0.03

ABVC BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0.142	/	14.463
	=	0.01

ABVC BioPharma (NAS:ABVC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ABVC BioPharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ABVC BioPharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ABVC BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABVC BioPharma Inc (NAS:ABVC) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538

Website

https://www.abvcpharma.com

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Executives

Shuling Jiang	director, 10 percent owner	44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Shih-chen Tseng	director	5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065
Yoshinobu Odaira	director	4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1
Norimi Sakamoto	director	4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1
Shin-yu Miao	director	NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676
Tsung Shann Jiang	director, officer: CSO and Director	1197 LA PLURISSIMA PL, FREMONT CA 94539
Eugene Jiang	director, officer: Chairman of the Board & CBO	1197 LA PLURISSIMA PL, FREMONT CA 94539
Chang-jen Jiang	director	1197 LA PLURISSIMA PL, FREMONT CA 94539
Yen-hsin Chou	director	13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413
Chi-hsin Richard King	officer: Chief Scientific Officer	11907 GRANT PLACE, SAINT LOUIS MO 63131
Howard Doong	officer: Chief Executive Officer	44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Chihliang An	officer: Chief Financial Officer	32458 JEAN DR, UNION CITY CA 94587
Tsang Ming Jiang	director	1197 LA PURISSIMA PL, FREMONT CA 94539
Shulamit Lazar	director, 10 percent owner, officer: President,Secretary,Treasurer	8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069
Kevin Patrick Stolz	officer: CFO & Controller	2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326